[心脏收缩性调制疗法:分子机制和临床应用的逻辑在心力衰竭与心缩和心缩功能障碍]
Alberto Guarnaccia1, Matteo Dal Ferro1, Mauro Biffi2
1Dipartimento Cardiovascolare, Centro per la Diagnosi e Cura delle Cardiomiopatie, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) e Università degli Studi di Trieste, Trieste.
概括
心脏收缩性调制 (CCM) 疗法可以改善心脏功能和心脏衰竭患者的心脏重塑,而不会增加氧气需求. 本综述探讨了CCM的使用情况.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
背景情况:
- 心力衰竭 (HF) 是一种复杂的疾病,其特点是心脏功能受损.
- 目前对HF的治疗有局限性,需要新的治疗方法.
研究的目的:
- 审查心脏收缩性调制 (CCM) 治疗的病理生理学方面和分子机制.
- 批判性地讨论支持心力衰竭患者CCM治疗的临床试验数据.
- 探索CCM治疗的潜在新应用.
主要方法:
- 对CCM的病理生理学方面和分子机制的文献综述.
- 对CCM治疗临床试验的科学证据的分析.
- 讨论CCM在细胞水平的影响.
主要成果:
- CCM疗法引起了生理细胞反应,从而提高了心脏性能.
- 在心力衰竭患者中,CCM疗法导致逆心室重塑.
- 该疗法可以改善心脏功能,而不会增加心肌氧消耗.
结论:
- CCM疗法在治疗心力衰竭方面是一个有希望的进步.
- 对新应用的进一步研究和建立患者登记册是有必要的.
相关概念视频
Cardiomyopathy V: Interprofessional Care
16
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Heart Failure V: Medical Management
14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14
Heart Failure Drugs: Inotropic Agents
626
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
626
Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16


